Previous 10 | Next 10 |
home / stock / sdmhf / sdmhf news
2023-04-03 13:00:00 ET Summary Sartorius announced the 2.4 billion euro acquisition of Polyplus. Polyplus is producing transfection reagents and generates <100 million euros in revenues. The acquisition appears to be very expensive and management has not explained the reaso...
2023-04-02 10:00:40 ET Summary In October I showcased my full portfolio. For my 100th Seeking Alpha article I decided to post an update and show how my portfolio developed. I sold out of 3 companies and added 6 new companies. I've contributed to Seeking Alpha for ove...
Sartorius Stedim Biotech S.A. (SDMHF) Q4 2022 Earnings Conference Call January 26, 2023, 09:30 AM ET Company Participants Joachim Kreuzburg - CEO Rainer Lehmann - CFO, Member of Executive Board Conference Call Participants Odysseas Manesiotis - Berenberg Ma...
Sartorius Stedim Biotech S.A. ( OTCPK:SDMHF ): FY GAAP EPS of € 8.64. Revenue of € 3.49M (+21.2% Y/Y). For further details see: Sartorius Stedim Biotech S.A. GAAP EPS of €8.64, revenue of €3.49M
Sartorius Stedim Biotech press release ( OTCPK:SDMHF ): 9M GAAP EPS of €6.58. Revenue of €2.6B (+23.2% Y/Y). Sales revenue up 17.0% in constant currencies, underlying EBITDA margin at 35.0%. Outlook for 2022 specified : Sales revenue growth ...
Nine-month results 2022 of Sartorius Stedim Biotech PR Newswire Sales revenue up 17.0 percent in constant currencies, underlying EBITDA margin at 35.0 percent Overall market situation characterized by innovations and strong growth drivers; current development as ex...
Summary I'm focused on high-quality companies with growing free cash flows per share. I group my portfolio into 4 buckets: Great capital allocations, Tech Leaders, (unprofitable) High-growth and short-term trades. I want to own companies with great management so that I can sle...
Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions PR Newswire UK-based Albumedix Ltd. is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company Re...
Sartorius Stedim Biotech S.A. press release ( OTCPK:SDMHF ): 1H GAAP EPS of €4.40. Revenue of €1.72B (+27.4% Y/Y). 2022 outlook confirmed: Sales revenue expected to rise by 15 to 19 percent vs. estimated growth of 9.92% Y/Y and underlying ...
Half-year results 2022 of Sartorius Stedim Biotech PR Newswire AUBAGNE, France , July 21, 2022 Sales revenue up 22.1 percent in constant currencies, underlying EBITDA margin 35.2 percent 2022 outlook confirmed: Sales revenue expected...
News, Short Squeeze, Breakout and More Instantly...
Sartorius Stedim Biotech Company Name:
SDMHF Stock Symbol:
OTCMKTS Market:
Nine-month results 2022 of Sartorius Stedim Biotech PR Newswire Sales revenue up 17.0 percent in constant currencies, underlying EBITDA margin at 35.0 percent Overall market situation characterized by innovations and strong growth drivers; current development as ex...
Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions PR Newswire UK-based Albumedix Ltd. is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company Re...
Half-year results 2022 of Sartorius Stedim Biotech PR Newswire AUBAGNE, France , July 21, 2022 Sales revenue up 22.1 percent in constant currencies, underlying EBITDA margin 35.2 percent 2022 outlook confirmed: Sales revenue expected...